Cyxone

Cyxone AB is a Swedish biotechnology company founded in 2015 with the goal of developing drugs using cyclic peptide technology, which can significantly improve the quality of life for patients with severe autoimmune diseases. The company operates through an international network of diverse experts from the fields of research, development, and manufacturing, including scientific founders from Austria and Germany. Its motivation is to develop a robust drug portfolio that employs innovative and effective treatment methods to reduce side effects and slow disease progression, thereby improving the quality of life for people affected by severe immune-related conditions. Cyxone's portfolio is based on a solid research platform that possesses a biomolecule proven to function as a human therapeutic. The company’s development pipeline includes Rabeximod in Phase II clinical trials for rheumatoid arthritis (RA) and T20K in Phase I clinical trials for multiple sclerosis (MS). In the future, Cyxone will also leverage its cyclic peptide technology to develop new structures, which may prove beneficial for patients in other disease areas.